Reviva Pharmaceuticals Holdings, Inc.

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/ CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to […] The post Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference appeared first on Reviva Pharmaceuticals.

– U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 – – FDA feedback on use of new brilaroxazine formulation in the RECOVER-2 trial and NDA expected Q4 2026 – – Patient enrollment in RECOVER-2 registrational Phase 3 […] The post Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights appeared first on Reviva Pharmaceuticals.

– The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at VirtualInvestorConferences.com – CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that […] The post Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th appeared first on Reviva Pharmaceuticals.

CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO […] The post Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase appeared first on Reviva Pharmaceuticals.

– Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 – – FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 –– Initiation of patient enrollment in RECOVER-2 registrational Phase 3 […] The post Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights appeared first on Reviva Pharmaceuticals.

CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO […] The post Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications appeared first on Reviva Pharmaceuticals.

CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a letter to shareholders from Founder, President, and […] The post Reviva Announces Letter to Shareholders appeared first on Reviva Pharmaceuticals.

– Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – – Current data package highlights well-tolerated long-term safety profile, broad-spectrum clinical activity, and favorable adherence for once daily brilaroxazine up to one year – – Initiation of RECOVER-2 registrational […] The post Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights appeared first on Reviva Pharmaceuticals.

CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the closing on March 20, 2026 of its previously announced […] The post Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering appeared first on Reviva Pharmaceuticals.

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with healthcare […] The post Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering appeared first on Reviva Pharmaceuticals.